Market Overview:
The Global Oligonucleotide Synthesis Market was valued around $5,928.6 million in 2021 and it is expected to reach around $18,972.5 million by the end of 2028, growing at CAGR of 17.5% during assessment period of 2022-2028.
Oligonucleotides are short fragments of nucleic acids that are synthesized using genetic engineering and enzyme chemistry. These are mostly used in laboratories in applications such as therapeutic, diagnostics as well as academic and industrial. These are used from initial research and screening through to target validation and drug production.

Market Impacting Factors:
The global oligonucleotide synthesis market is operating in its growth stage in its industry life cycle and huge growth opportunities are underway for this market going forward. Most of them are identified in research related field as oligonucleotide synthesis finds significant application in the field of research and development.
Since oligonucleotide finds application research fields growing investment by government in R&D along with increase in demand for oligo customization or custom oligo is the major growth drivers in this market. Growing pace of global R&D operations in pharma and biotech sector especially for novel products is creating space for custom oligo and this trend is likely strengthen over the next few years. At the same time, high cost of purification is also posing challenges which is also considered as the major growth restraint in the current scenario.
Factors such as rise in prevalence of infectious disease, patient awareness towards diagnosis through sequencing technology, and advancement in the field genomic research are also contributing to the growth of this market. Several biopharmaceutical companies have started developing in house oligonucleotides due to several reason, confidentiality being one of them. This in turn likely to restrain the revenue growth of service providers in this market. Companies are adopting collective approach in terms of developing products as well as exploring new emerging markets. Supply agreement and strategies collaboration s are among the frequently used strategies during 2020-2021 to gain competitive edge. As per our analysis, Merck, Thermo Fischer, and Danaher Corporation (IDT) are three market leaders shaping the growth of global oligonucleotide synthesis market. These players have collectively acquired over 50% market shares as of 2021.

Geographic Analysis:
North America is the market leader in the global oligonucleotide synthesis and the region is further expected to continue its global dominance over the forecast period as well. Some of the factors transforming the growth trajectory of this region are established healthcare industry, sophisticated healthcare as well as medical infrastructure, high healthcare spending, active presence of key industry players, and high number of players who have strategic pipeline in regards to the oligonucleotide synthesis. Additionally, availability of research grants and funding is further supporting the developments in oligonucleotide synthesis and creating space for revenue opportunities.
Asia Pacific oligonucleotide synthesis market is one of the fastest growing market across the globe. Across Asia Pacific, oligonucleotide synthesis technology is mainly adopted across key country level markets including China, India, Japan, Australia, and South Korea. Asia Pacific is anticipated to witness profitable revenue opportunities in the coming years as the region possess immense potential for oligonucleotide synthesis technology development due to rising number of cancer patients every year. Since, this technique is anticipated to be useful in the prevention and cure of complex conditions, such as cancer, cardiac disease or disorders, mental illnesses, and human immunodeficiency virus (HIV) infection; Asia Pacific region is expected to create lucrative growth opportunities, further supporting the Asia Pacific oligonucleotide synthesis market growth.

Competitive Scenario:
Major players operating in the global Oligonucleotide Synthesis market include DNA Technologies, Inc. (Part of Danaher Corporation), Merck KGaA, Eurofins Scientific SE, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., GE Healthcare, GeneDesign, Inc. (Part of Ajinomoto Co.,Inc.), Kaneka Eurogentec (Part of Kaneka Corporation), LGC Biosearch Technologies, Bio-synthesis Inc., TriLink BioTechnologies, LLC (Part of Maravai LifeSciences), and ATDBio Ltd. among others.

Market Segmentation
• By Product
◦ Oligonucleotide-based Drug
◦ Synthesized Oligonucleotide
◦ Reagent
◦ Equipment

• By Length
◦ 10
◦ 20
◦ 50
◦ 100
◦ 150
◦ 200

• By Application
◦ Therapeutic
▪ RNAi Oligonucleotide-based Therapy
▪ DNA/Antisense Oligonucleotide-based Therapy
▪ Immunotherapy (CpG Oligonucleotide-based Therapy)
▪ Nucleic Acid Aptamer
◦ Research
▪ PCR
▪ CRISPR
▪ NGS
▪ Pooled Oligos
▪ Gene Synthesis
▪ Other Research Applications
◦ Diagnostic

• By End User
◦ Hospital
◦ Pharmaceutical & Biotechnology Company
◦ Diagnostic Laboratory
◦ Others

• By Region
◦ North America (U.S., Canada, Mexico)
◦ Europe (Germany, France, Italy, Spain, UK, Rest of Europe)
◦ Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific)
◦ Latin America (Brazil, Argentina, Rest of LAMEA)
◦ Middle East & Africa (Saudi Arabia, UAE, Bahrain, South Africa, Rest of MEA)